An up­date on the End­points busi­ness mod­el — and how your com­pa­ny can di­rect­ly sup­port it

Pic­tured: The print-op­ti­mized ver­sion of End­points’ 2018 New Drug Ap­provals re­port. All paid sub­scribers will re­ceive a di­rect link to down­load the PDF + a copy of all our Q1 pay­wall sto­ries in print­able form, too.

Sign-up for En­ter­prise (com­pa­ny plan)
Sign-up for In­sid­er (in­di­vid­ual plan)


I want to give read­ers an up­date on the busi­ness front at End­points News, which is strong.

Two and a half years in — we’re prof­itable, about 14 peo­ple on the team and grow­ing, and 75,000 unique bio­phar­ma read­ers con­sume our news across all plat­forms on a week­ly ba­sis. Of that, 31,000 are what we con­sid­er “ba­sic sub­scribers” who re­ceive our dai­ly email re­ports and have opened or clicked on them in the last month, but haven’t up­grad­ed to paid sta­tus. And at the top we have 8,300 pre­mi­um sub­scribers who ei­ther di­rect­ly sup­port the work or are em­ployed at a com­pa­ny that does.

We reg­u­lar­ly scrub our email read­er­ship, too.

We’ve built a glob­al events fran­chise and con­vened over 2,000 at­ten­dees over the last 12 months in San Fran­cis­co, Boston, Lon­don, and Shang­hai. Lat­er this month we’ll be an­nounc­ing venues and dates for our en­tire 2019 line­up.

John Car­roll speaks at the US-Chi­na Bio­phar­ma In­no­va­tion and In­vest­ment Sum­mit in Shang­hai on Oc­to­ber 23, 2018

Click on the im­age to see the full-sized ver­sion


And we’ve done all of this with­out rais­ing any VC cash.

End­points is built to with­stand the storms en­velop­ing dig­i­tal me­dia to­day thanks to the di­rect sup­port of our En­ter­prise and In­sid­er sub­scribers.  We’re hir­ing new jour­nal­ists, plan to dou­ble the au­di­ence, and have moved in­to a new head­quar­ters in Lawrence, Kansas that’ll serve as the nerve-cen­ter for End­points’ next stage of in­no­va­tion. New hires in mar­ket­ing, sales, and op­er­a­tions are in the works now to sup­port that. There’s a web­site re­vamp on tap. And there’s just so much more news we’d like to cov­er in trans­la­tion­al sci­ence and out­sourc­ing.

Most im­por­tant­ly: Our fi­nan­cial in­cen­tives are tied to pro­duc­ing a jour­nal­ism prod­uct that serves the core bio­phar­ma read­er.

Haven’t joined yet? Now is a great time and you can see one of the ben­e­fits above: a print (yes, print!) ver­sion of the 2018 class of new drug ap­provals. You’ll al­so get ac­cess to the lat­est edi­tion of bio­phar­ma’s top 100 VCs, and the en­tire pay­wall li­brary.

The most im­por­tant way you can di­rect­ly sup­port End­points is hav­ing your com­pa­ny sub­scribe to our $1,000/year flat-rate En­ter­prise plan (signup link). That’s an “un­lim­it­ed li­cense” for every em­ploy­ee un­der your cor­po­rate ban­ner. All of your col­leagues get ac­cess to pay­wall con­tent, reprint rights, PDF ex­port, and your HR team gets two pre­mi­um job post­ings at End­points Ca­reers. We have a VIP sup­port team who’ll work with you to get End­points set up for the rest of your team, too.

It’s a great val­ue, and you’re sup­port­ing the most im­por­tant part of our mod­el. The pric­ing is trans­par­ent and so is our re­new­al process.

For in­di­vid­u­als, we of­fer the In­sid­er plan at $200/year. Ex­tra ben­e­fits on top of the pay­wall ac­cess in­clude dis­count­ed rates to our ma­jor glob­al events line­up.

We’re al­so start­ing a se­ries of sub­scriber-on­ly net­work­ing mix­ers for In­sid­ers. The very first one will be in Durham, NC on Thurs­day Feb­ru­ary 21 at 6pm. I’ll be there along with our VP/Part­ner­ships Mike Peck. In­sid­ers will get an email next week with signup de­tails on this one and our fu­ture slate.

Grow­ing Plans

We’re go­ing through a ma­jor plat­form over­haul this year.

The look and feel of End­points hasn’t changed since we launched in June 2016. The orig­i­nal goal of our de­sign is to de­liv­er news with­out un­nec­es­sary or­na­ments, with a user ex­pe­ri­ence that feels fa­mil­iar no mat­ter what de­vice you’re on. But we’ve pub­lished over 5,000 news ar­ti­cles and near­ly 700 dai­ly re­ports now in the End­points style, and with that ex­pe­ri­ence we’ve iden­ti­fied a num­ber of ar­eas we can im­prove on. Some of it will be in­cre­men­tal like bet­ter search and im­prov­ing the archives. Oth­ers will be more vis­i­ble and feel like brand new fea­tures.

Ad­ver­tis­ing

Sub­scrip­tions are the lifeblood of this com­pa­ny. But in or­der to de­vel­op a sus­tained im­pact be­fit­ting a ma­jor news or­ga­ni­za­tion, ar­ti­cles must be able to trav­el far and wide, eas­i­ly dis­cov­er­able by new au­di­ences. Oth­er­wise, we run the risk of be­com­ing an in­sid­ers-on­ly re­port.

That is where ad­ver­tis­ing comes in. But noth­ing we do there is tra­di­tion­al.

I don’t be­lieve in squeez­ing web pages hard for lit­tle juice. That’s es­sen­tial­ly what many news pub­lish­ers do when you see pro­mot­ed links and ads that are at best ir­rel­e­vant and at worst have fol­lowed you around the In­ter­net to sell you some­thing you searched on ear­li­er. That kind of ap­proach cheap­ens the qual­i­ty of the con­tent sur­round­ing it, in my view. It has no place on a busi­ness news web­site.

Every ad unit you see on End­points is pur­chased in-house. These are high qual­i­ty im­pres­sions that are rel­e­vant to bio­phar­ma, brought to you by ad­ver­tis­ers that have been vet­ted. Our busi­ness team is led by Mike Peck, who comes to End­points af­ter serv­ing as a VP at Forbes and the New York Times. Mar­ket­ing pros can reach him at mike@end­pointsnews.com.

Busi­ness Mod­el

Sub­scrip­tions, events, ad­ver­tis­ing — in or­der of im­por­tance, that is the End­points busi­ness mod­el. Our mis­sion is to pro­duce the best dai­ly news re­port in bio­phar­ma, writ­ten for our core read­ers, but to make it as wide­ly avail­able as pos­si­ble so it has an im­pact and is dis­cov­er­able by new read­ers.

If you need End­points, we def­i­nite­ly need you. Again the best way to sup­port us is hav­ing your com­pa­ny sub­scribe to our $1,000/year flat-rate En­ter­prise plan (signup link). In­di­vid­u­als can signup for In­sid­er here.

To all of you who’ve joined — thank you. We’re build­ing some­thing to­geth­er.

Michel Vounatsos, Biogen CEO (via YouTube)

UP­DAT­ED: Bio­gen spot­lights a pair of painful pipeline set­backs as ad­u­canum­ab show­down looms at the FDA

Biogen has flagged a pair of setbacks in the pipeline, spotlighting the final failure for a one-time top MS prospect while scrapping a gene therapy for SMA after the IND was put on hold due to toxicity.

Both failures will raise the stakes even higher on aducanumab, the Alzheimer’s drug that Biogen is betting the ranch on, determined to pursue an FDA OK despite significant skepticism they can make it with mixed results and a reliance on post hoc data mining. And the failures are being reported as Biogen was forced to cut its profit forecast for 2020 as a generic rival started to erode their big franchise drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,200+ biopharma pros reading Endpoints daily — and it's free.

A new chap­ter in the de­cen­tral­ized clin­i­cal tri­al ap­proach

Despite the promised decentralized trial revolution, we haven’t yet moved the needle in a significant way, although we are seeing far bolder commitments to this as we continue to experience the pandemic restrictions for some time to come. The vision of grandeur is one thing, but operationalizing and execution are another and recognising that change, particularly mid-flight on studies, is worthy of thorough evaluation and consideration in order to achieve success. Here we will discuss one of the critical building blocks of a Decentralized and Remote Trial strategy: TeleConsent; more than paper under glass, it is a paradigm change and key digital enabler.

Philipp Spycher

Promis­ing bet­ter link­er tech to ADC field, Araris has 'very, very am­bi­tious' plans for the clin­ic

A couple months after raising CHF 2.5 million ($2.76 million) in initial seed funding, one-year-old Araris Biotech is topping off the round with another CHF 12.7 million ($14 million).

The Paul Scherrer Institute and ETH Zurich spinout now has CHF 15.2 million to work with, and CEO Philipp Spycher has big plans. He hopes to bring one of the company’s antibody-drug conjugates (ADC) to the clinic by late 2022 or early 2023. “It’s very, very ambitious, but we are very optimistic that we actually can make it,” he said.

Stephen Hahn, FDA commissioner (AP Images)

As FDA sets the stage for the first Covid-19 vac­cine EUAs, some big play­ers are ask­ing for a tweak of the guide­lines

Setting the stage for an extraordinary one-day meeting of the Vaccines and Related Biological Products Advisory Committee this Thursday, the FDA has cleared 2 experts of financial conflicts to help beef up the committee. And regulators went on to specify the safety, efficacy and CMC input they’re looking for on EUAs, before they move on to the full BLA approval process.

All of this has already been spelled out to the developers. But the devil is in the details, and it’s clear from the first round of posted responses that some of the top players — including J&J and Pfizer — would like some adjustments and added feedback. And on Thursday, the experts can offer their own thoughts on shaping the first OKs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,200+ biopharma pros reading Endpoints daily — and it's free.

David Hung (file photo)

Mas­ter deal­mak­er David Hung re­tools a SPAC sedan in­to a fi­nanc­ing mus­cle ve­hi­cle that leaves his can­cer start­up with $850M and a place on Wall Street

It’s only right that one of the industry’s top dealmakers just completed one of the biggest SPAC-related deals in the pipeline.

David Hung, of Medivation fame, has completed a back flip into the market, merging with EcoR1 Capital’s SPAC Panacea and landing neatly on Wall Street with an $NUVB stock ticker after filling out the blank check in his name. In addition to the $144 million held in the SPAC — provided none of the investors opt out — Hung is getting ahold of $500 million more being chipped in by a slate of institutional investors who feel that Hung could have the keys to another Medivation-style success.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,200+ biopharma pros reading Endpoints daily — and it's free.

Pfizer CEO Albert Bourla (Drew Angerer/Getty Images)

Pfiz­er is on the verge of claim­ing a multi­bil­lion-dol­lar first-mover ad­van­tage with their Covid-19 vac­cine — an­a­lyst

From the beginning, Pfizer CEO Albert Bourla eschewed government funding for his Covid-19 vaccine work with BioNTech, willing to take all the $2 billion-plus risk of a lightning-fast development campaign in exchange for all the rewards that could fall its way with success. And now that the pharma giant has seized a solid lead in the race to the market, those rewards loom large.

SVB Leerink’s Geoff Porges has been running the numbers on Pfizer’s vaccine, the mRNA BNT162b2 program that the German biotech partnered on. And he sees a $3.5 billion peak in windfall revenue next year alone. Even after the pandemic is brought to heel, though, Porges sees a continuing blockbuster role for this vaccine as people around the world look to guard against a new, thoroughly endemic virus that will pose a permanent threat.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,200+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: CRISPR Ther­a­peu­tics gets a snap­shot of off-the-shelf CAR-T suc­cess in B-cell ma­lig­nan­cies — marred by the death of a pa­tient

Just days after scientific founder Emmanuelle Charpentier shared the Nobel prize for her work on CRISPR/Cas9, CRISPR Therapeutics $CRSP is showing off a snapshot of success in their early-stage study for an off-the-shelf CAR-T approach to CD19+ B cell malignancies — a snapshot marred by the death of a patient who had been given a high dose of the treatment.

Using their gene editing tech, researchers for CRISPR engineered cells from healthy donors into an attack vehicle aimed at cancer, something that has been achieved with great success using patients’ own cells — the autologous approach. But autologous CAR-T is hampered by the more complex vein-to-vein requirement that delays treatment, and now CRISPR Therapeutics along with other players like Allogene are determined to replace the pioneers with CAR-T 2.0.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,200+ biopharma pros reading Endpoints daily — and it's free.

RBC's Bri­an Abra­hams holds a mock ad­comm on Bio­gen's iffy ad­u­canum­ab da­ta — and most of these ex­perts don't see a path to an ap­proval

As catalysts go, few loom larger than the aducanumab adcomm slated for Nov. 6.

With its big franchise under assault, Biogen is betting the ranch that its mixed late-stage Alzheimer’s data can squeak past the experts and regulators and get onto the market. And the topic — after a decade of Alzheimer’s R&D disasters in what still represents the El Dorado of drug markets — remains in the center ring of discussions around late-stage pipeline prospects.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,200+ biopharma pros reading Endpoints daily — and it's free.

Giovanni Caforio, Bristol Myers Squibb CEO (Christopher Goodney/Bloomberg via Getty Images)

Here's how Bris­tol My­er­s' CEO Gio­van­ni Caforio com­plet­ed a $13B buy­out: He moved fast, upped the bid quick­ly and de­mand­ed every­one to keep up

Bristol Myers Squibb CEO Giovanni Caforio does not waste time. He also likes everyone around him to keep up.

Anyone reading over the insider account filed with the SEC of the back-and-forth over his $13 billion buyout of MyoKardia $MYOK could reach only one conclusion: The CEO who had willingly crafted a $74 billion Celgene acquisition had found something else he liked — and he was willing to pay a nice premium to get it.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 92,200+ biopharma pros reading Endpoints daily — and it's free.